These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35084647)

  • 1. Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA.
    Owusu-Edusei K; Deb A; Johnson KD
    Infect Dis Ther; 2022 Jun; 11(3):987-999. PubMed ID: 35084647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States.
    Hu T; Weiss T; Owusu-Edusei K; Petigara T
    J Med Econ; 2020 Dec; 23(12):1653-1660. PubMed ID: 33084447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries.
    Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
    J Med Econ; 2021; 24(1):1098-1107. PubMed ID: 34461796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong.
    Mohanty S; Hu T; Yang G; Khan TK; Owusu-Edusei K; Sukarom I
    Hum Vaccin Immunother; 2022 Nov; 18(5):2046433. PubMed ID: 35420975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
    Platt HL; Cardona JF; Haranaka M; Schwartz HI; Narejos Perez S; Dowell A; Chang CJ; Dagan R; Tamms GM; Sterling T; Morgan L; Shi Y; Pedley A; Musey LK; Buchwald UK
    Vaccine; 2022 Jan; 40(1):162-172. PubMed ID: 34507861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).
    Banniettis N; Wysocki J; Szenborn L; Phongsamart W; Pitisuttithum P; Rämet M; Richmond P; Shi Y; Dagan R; Good L; Papa M; Lupinacci R; McFetridge R; Tamms G; Churchill C; Musey L; Bickham K;
    Vaccine; 2022 Oct; 40(44):6315-6325. PubMed ID: 36150974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifetime Health and Economic Burden of Invasive Pneumococcal Diseases Attributable to V116 Serotypes Among Adults in the United States.
    Yi Z; Johnson KD; Owusu-Edusei K
    Infect Dis Ther; 2024 Jul; 13(7):1501-1514. PubMed ID: 38796565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes.
    Amin-Chowdhury Z; Groves N; Sheppard CL; Litt D; Fry NK; Andrews N; Ladhani SN
    Vaccine; 2021 Apr; 39(14):1997-2004. PubMed ID: 33715901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland.
    Deb A; Guggisberg P; Mutschler T; Owusu-Edusei K; Bencina G; Johnson KD; Ignacio T; Mathijssen DAR; Qendri V
    Expert Rev Vaccines; 2022 May; 21(5):711-722. PubMed ID: 35220875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
    Song JY; Chang CJ; Andrews C; Diez-Domingo J; Oh MD; Dagan R; Hartzel J; Pedley A; Li J; Sterling T; Tamms G; Chiarappa JA; Lutkiewicz J; Musey L; Tu Y; Buchwald UK;
    Vaccine; 2021 Oct; 39(43):6422-6436. PubMed ID: 34489128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033).
    Suzuki H; Fujita H; Iwai K; Kuroki H; Taniyama K; Shizuya T; Kishino H; Igarashi R; Shirakawa M; Sawata M
    Vaccine; 2023 Jul; 41(34):4933-4940. PubMed ID: 37344262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of pediatric immunization program with 15-valent pneumococcal conjugate vaccine in Japan.
    Tajima A; Abe M; Weaver J; Huang M
    J Med Econ; 2023; 26(1):1034-1046. PubMed ID: 37555281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).
    Bili A; Dobson S; Quinones J; Phongsamart W; Oberdorfer P; Kosalaraksa P; Dagan R; Richmond P; Wilck M; Vallejos W; Nunn C; McFetridge R; Tamms G; Fu R; Lupinacci R; Musey L; Banniettis N; Bickham K;
    Vaccine; 2023 Jan; 41(3):657-665. PubMed ID: 36522265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).
    Hammitt LL; Quinn D; Janczewska E; Pasquel FJ; Tytus R; Rajender Reddy K; Abarca K; Khaertynova IM; Dagan R; McCauley J; Cheon K; Pedley A; Sterling T; Tamms G; Musey L; Buchwald UK
    Open Forum Infect Dis; 2022 Mar; 9(3):ofab605. PubMed ID: 35146039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
    Mohapi L; Pinedo Y; Osiyemi O; Supparatpinyo K; Ratanasuwan W; Molina JM; Dagan R; Tamms G; Sterling T; Zhang Y; Pedley A; Hartzel J; Kan Y; Hurtado K; Musey L; Simon JK; Buchwald UK;
    AIDS; 2022 Mar; 36(3):373-382. PubMed ID: 34750291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM).
    Wilck M; Cornely OA; Cordonnier C; Velez JD; Ljungman P; Maertens J; Selleslag D; Mullane KM; Nabhan S; Chen Q; Dagan R; Richmond P; Daus C; Geddie K; Tamms G; Sterling T; Patel SM; Shekar T; Musey L; Buchwald UK;
    Clin Infect Dis; 2023 Oct; 77(8):1102-1110. PubMed ID: 37338158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).
    Simon JK; Staerke NB; Hemming-Harlo M; Layle S; Dagan R; Shekar T; Pedley A; Jumes P; Tamms G; Sterling T; Musey L; Buchwald UK;
    Vaccine; 2022 Feb; 40(9):1342-1351. PubMed ID: 35039194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study.
    Quinn CT; Wiedmann RT; Jarovsky D; Lopez-Medina E; Rodriguez HM; Papa M; Boggio G; Shou Q; Dagan R; Richmond P; Feemster K; McFetridge R; Tamms G; Lupinacci R; Musey L; Bickham K
    Blood Adv; 2023 Feb; 7(3):414-421. PubMed ID: 36383730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective.
    Li X; Warren S; Rozenbaum MH; Perdrizet J
    Infect Dis Ther; 2023 Mar; 12(3):997-1006. PubMed ID: 36867396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
    Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
    Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.